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Abstract
Background Pancreatic metastases in childhood cancer
have been rarely reported in the radiology literature
although ample evidence exists in pathology reports for
its occurrence in patients with alveolar rhabdomyosarcomas
(RMS).
Objective Assess the occurrence of pancreatic metastases in
alveolar rhabdomyosarcomas, increase awareness of this
association and reassess current staging protocols.
Materials and methods Three major oncology centers
reviewed their records and imaging examinations. Patients’
history and demographics, primary tumor site and histology,
presence of tumor recurrence, and presence and location of
other metastases were reviewed.
Results Pancreatic metastases occurred in eight patients
with alveolar RMS. Four of these presented at diagnosis
and four with disease recurrence. In recurrent disease, the
duration between the diagnosis of the primary tumor and
pancreatic metastases varied from 8 months to 6 years
(mean±SD: 2.38±2.49 years). In all patients who received
PET scans, pancreatic metastases showed a marked FDG-
uptake, but had variable detectability with CT. Pancreatic
metastases were not associated with certain primary tumor
locations or presence of other metastases, mandating an
evaluation of the pancreas in all cases of alveolar
rhabdomyosarcomas.
Conclusion Radiologists should be sensitized and actively
evaluate the pancreas in patients with alveolar RMS.
Optimizing CT and PET-CT protocols may increase the
diagnostic yield.
Keywords Alveolar rhabdomyosarcoma .Metastasis .
Pancreas . Pancreatic metastasis . PET. CT. Children
Introduction
Rhabdomyosarcoma (RMS) represents the most common
soft-tissue sarcoma in children, with an incidence of 4.3
new cases per million children and adolescents younger
than 20 years [1]. RMS originates from striated muscle cells
or their mesenchymal precursors and occurs in a large
variety of locations, such as the head and neck, pelvis and
extremities [2]. Histologically, RMS can be classified as
either embryonal (60%), alveolar (20%), undifferentiated or
miscellaneous subtypes [3]. Alveolar RMS is associated
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with an aggressive course and a poor outcome [3]. Alveolar
RMS frequently has genomic alterations such as chromo-
somal translocations with fusion of the FKHR gene on
chromosome 13 with either PAX 3 (on chromosome 2) or
PAX 7 (on chromosome 1) [4], which lead to chimeric
fusion proteins that alter cellular transcription and amplify
cell proliferation [4]. While multimodality treatment studies
and specifically the use of radiation therapy have shown
improved outcomes [5], the development of distant metas-
tases still correlates with 5-year survival rates of less than
20% [3, 6]. Metastatic disease is thought to involve most
commonly the lungs, bone, bone marrow and lymph nodes
[6] and rhabdomyosarcomas have a propensity to involve
unusual sites such as the breast, testes and subcutaneous
tissue [7]. In addition, previous autopsy studies reported an
incidence of pancreatic metastases in 67% of patients who
died from metastatic alveolar RMS [7]. Conversely, only
reports of isolated cases of patients with alveolar RMS and
pancreatic metastases can be found in the radiology
literature [2, 8–10]. Here, we report a series of eight cases
of metastatic involvement of the pancreas in patients with
alveolar RMS. We want to sensitize radiologists to the
possible association of pancreatic metastases in patients
with alveolar RMS, which warrants careful and active
evaluations of the pancreas in these patients and optimization
of imaging protocols.
Materials and methods
The Committee on Human Research at three major
pediatric oncology centers approved this retrospective
evaluation. Pediatric radiologists at UCSF Children’s
Hospital, Hospital for Sick Children, which is affiliated
with the University of Toronto, and St. Jude Children’s
Research Hospital reviewed their records of the last 11 years
(1998–2009) and identified eight patients with biopsy-
proven alveolar RMS and pancreatic metastases out of a
total of 71 cases (males:females=34:37) of alveolar
rhabdomyosarcoma. All clinical data and imaging studies
of these patients were reviewed retrospectively, including
patient’s age, gender, clinical presentation, primary tumor
location, presence or absence of metastases at diagnosis,
type of therapy, presence or absence of recurrence after
therapy, metastases at time of recurrence, duration between
initial diagnosis and imaging findings of pancreatic metastases
and final outcome.
The eight subjects included three males and five females,
ages 1.8 to 35.0 years (mean±SD 8.0±4.4 years). Interest-
ingly, all younger patients were females while the males in
this series presented with disease in the pubertal and post-
pubertal years. The characteristics of the patients are
summarized in Table 1. The diagnosis of alveolar RMS was
confirmed on histologic biopsy of the primary tumor. Medical
history, treatment history and imaging studies were reviewed.
Evaluations of imaging studies included the following:
Imaging studies at diagnosis of the primary tumor
revealed that all eight patients received an MR and three
had a CT of the primary tumor. In addition, all patients
received a contrast-enhanced chest CT (CECT) at diagno-
sis. Abdominal axial contrast-enhanced CT scans covered
the pancreas in accordance to the Children’s Oncology
Group (COG) guidelines for initial staging in all the patients.
Three patients received a PET and two received a PET-CT.
Three patients didn’t receive any PET examination.
The patients were followed with MRI of the primary
tumor and CECT of the chest at weeks 6, 19, and 34 during
therapy and at the end of therapy at week 54 per COG
protocols. In addition, abdominal CECT was obtained in all
patients at weeks 6, 19, 34 and 54 except four instances,
when non-enhanced abdominal CTs were obtained in two
patients at weeks 6 and 34 of their respective follow-ups.
PET-CT studies were employed for four of these patients
who were deemed to be high risk or for evaluating
suspected widespread metastases for treatment planning. All
imaging studies were retrospectively reviewed by two
independent pediatric radiologists at each center concerning
the presence, number, size, location and imaging character-
istics of pancreatic metastases.
In acquiring the diagnostic-quality CTs associated with this
study, the effective dose ranged between 1.76 and 24.7 mSv
for all patients. The radiopharmaceutical 18F-FDG was
intravenously injected at a rate of 0.21 mCi/kg of body weight
(7.78 MBq/kg) with a mean activity of 14.37 mCi
(531.69 MBq/kg) administered. Thus, based on the biodis-
tribution of 18F-FDG and the ICRP internal dosimetry model,
the radiation exposure of a patient who received the mean
dose of 18F-FDG was 1.58 rem (12.2 mSv; http://www.
internaldosimetry.com; CDE Dosimetry Services, Inc. 2001).
The combination of PET and CT provided a mean effective
dose of 23.49 mSv (range 19.12 to 55.06 mSv).
Results
The seven children included three boys and five girls, ages
1.8 to 20.0 years (mean±SD: 8.0±4.4 years). In addition,
an adult patient (35-year-old man) with alveolar RMS was
identified. Clinical findings of these patients are summa-
rized in Table 1. All patients had a biopsy-proven alveolar
RMS at variable locations, in the upper extremity (4 cases),
head and neck (2), lower extremity (1) and pelvis (1). The
chemotherapy regimens instituted included the following
protocols: (1) POGD-9803, regimen B with vincristine,
actinomycin and cyclophosphamide; (2) Irinotectan along
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with radiotherapy and autologous bone marrow transplan-
tation; (3) D9802, regimen B (vincristine, actinomycin and
cyclophosphamide, regimen B). The common drugs that
were used in all patients were vincrisitine, actinomycin and
cyclophosphamide.
Four patients had pancreatic metastases diagnosed at
initial presentation while four patients presented with
pancreatic metastases at the time of disease recurrence.
The age at diagnosis of the pancreatic metastases varied
from 2 years to 35 years (mean±SD: 15.38±10.98). The
duration between the diagnosis of the primary tumor and
that of pancreatic metastases in patients with recurrent
disease varied from 8 months to 6 years (mean±SD: 2.38±
2.49 years). In this small cohort of patients, the pancreatic
metastases were observed with no relation to a specific
primary tumor site. Six of our patients had upper extremity,
head and neck primary disease and we note current COG
recommendations regarding abdominal CT scans are only for
lower extremity, genitourinary and abdominal tumors. Six
pancreatic metastasis were clinically asymptomatic with the
diagnosis being established on routine CT or PET staging or
re-staging examinations. Two patients were symptomatic and
presented with obstructive jaundice in one case (Fig. 1) and
gastric outlet obstruction in the other (Fig. 2).
All CT imaging studies revealed metastases in the pancreas
as irregular, hypodense lesions compared to surrounding
enhancing pancreatic tissue on venous phase post-contrast
scans (Figs. 1–4). Pancreatic metastases presented as solitary
lesions in six patients (Figs. 1–4), two focal lesions in one
patient and multiple lesions geographically involving the
pancreas in one patient. The lesions were all well defined
(n=8) and located in the head (four lesions), body (4) or tail
Fig. 1 A 17-year-old boy with previously treated alveolar RMS of the
right hand presented with increasing right upper quadrant abdominal
pain and pruritus. a Axial CECT scan demonstrates a large, hypodense
mass (*) in the head of the pancreas. The mass caused symptoms of
obstructive jaundice. b PET scan at the same level depicts marked
radiotracer uptake (asterisk) of this lesion
Fig. 2 A 6-year-old girl with locally recurrent and metastastic
alveolar RMS of the left upper extremity. a Axial CECT scan of the
abdomen shows a large, irregular, inhomogeneous hypodense lesion
(*) in the tail of the pancreas. b Axial CT scan obtained 5 weeks later
demonstrates marked interval growth of the lesion and development of
multiple new intrahepatic lesions (arrows)
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(2) of the pancreas. One patient showed an associated intra-
and extrahepatic bile duct dilation (Fig. 1). PET scans were
performed in three patients (Fig. 3) and an integrated PET-
CT scan (Figs. 1 and 4) was obtained in two. All pancreatic
metastases evaluated with PET showed significant FDG-
uptake in the region of the pancreas. Two of these
metastases showed a rim-enhancement, without any central
enhancement on CT but marked central FDG-uptake on
PET scans (Fig. 4). Our data showed that one pancreatic
metastasis in our cohort was difficult to detect on contrast-
enhanced CT as it presented as an ill-defined distortion in
the shape of the tail of the pancreas rather than a discrete
mass or a nodule (Fig. 3). This and one other metastasis
were initially missed on non-contrast enhanced CT, while
Fig. 3 A 14-year-old girl with alveolar RMS of the pelvis and
pancreatic metastases. a Axial contrast-enhanced abdominal CT image
demonstrates a small, hypodense mass in the body of the pancreas,
which was initially missed on CECTs and detected on PET-CT
imaging (arrows). b Axial CT obtained during PET-CT shows the area
of the pancreas metastasis (arrow) and subcutaneous (S) and
peritoneal metastases (P). c Co-registered axial PET image, at the
same level shown in (b), demonstrates small, intensely FDG-avid
pancreas (arrow) and subcutaneous (S) and peritoneal (P) metastases.
Two foci of FDG activity in the retroperitoneum correspond to normal
kidneys (K)
Fig. 4 A 20-year-old man with recurrent alveolar RMS of the right arm with widespread metastases. a Axial CECT scan demonstrates a low
attenuation mass (*) in the head of the pancreas. b PET scan at the level of the same lesion shows marked FDG uptake (arrow)
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PET or PET-CT easily diagnosed all pancreas metastases as
hot spots.
In all patients, pancreatic metastases were diagnosed
together with other metastases at extra-abdominal sites,
such as lymph nodes (n=6), bony metastases (n=6), lung
(n=2), brain (n=3), bone marrow (n=1), breast (n=1) or
soft tissue (n=4). Four patients had pancreatic metastases
without any other metastases in the abdomen. The remaining
four patients had pancreatic involvement with additional
abdominal metastases in the liver (n=2), adrenal glands
(n=1) or lymph nodes (n=2). These additional intrabdominal
metastases were diagnosed at the same time as the pancreatic
metastases. None of the patients had isolated metastases in
the pancreas without any metastatic involvement elsewhere
in the body.
The outcome was dismal in seven of these patients who
succumbed to widespread metastatic disease. The pancreatic
metastases, however, can’t be attributed to as an independent
poor prognostic factor as it always occurred in the setting of
widespread metastatic disease. One patient is currently being
followed up on chemotherapy but also has a poor prognosis
due to widespread metastatic involvement.
Discussion
Our retrospective study reveals an unexpected occurrence
of pancreatic metastases in patients with alveolar RMS. The
pancreas has been traditionally regarded as a rare site for
metastases in children with cancer. However, according to
an autopsy report of 57 children who died from alveolar
RMS, 67% had pancreatic metastases, making the pancreas
the third most common site for metastases in these patients
after lung and lymph nodes [7]. In spite of this high
number, the presence of pancreatic metastases in RMS has
been rarely reported in the radiology literature [2, 8, 11,
12]. This discrepancy between pathology and radiology
observations may be due to different evaluated patient
populations (selected patients with fatal outcome in the
cited pathology report versus all patients with RMS
evaluated on imaging studies), limited evaluations of the
pancreas with standard imaging protocols and limited
sensitivity of unenhanced CTs for the detection of pancre-
atic metastases among other parenchymal lesions.
There was no apparent correlation between the location of
the primary tumor and the size and location of metastases in
our small cohort. This is contrary to the usual thought that
suchmetastases are usually expectedwith lower extremity and
genitourinary tumors. According to the guidelines issued by
the COG, the initial staging examinations for soft-tissue
sarcomas include a CTorMR scan for evaluating the liver and
retroperitoneum. PET or PET-CT examinations are not
included. It should also be noted that National Cancer Institute
(NCI) does identify that PET can help detect metastases
otherwise undetected on conventional imaging and can be
considered as a tool although not recommended by the current
treatment protocols (http://www.cancer.gov/cancertopics/pdq/
treatment/childrhabdomyosarcoma/HealthProfessional/
page4#Reference4.2). Our data showed that two pancreatic
metastasis in our study cohort were missed initially on CT,
while PET or PET-CT easily diagnosed all pancreas
metastases as hot spots due to their highly increased
metabolic activity compared to the normal pancreas. Other
authors also reported that they initially overlooked unsus-
pected pancreatic metastases in patients with RMS and that
these were readily diagnosed on PET scans [8]. Also as
detailed in the results section, pancreatic metastases may
have only rim enhancement on CT studies but these same
metastases avidly uptake FDG on PET imaging. This may be
secondary to an extremely cellular center, which is under-
perfused leading to the discrepancy in CT and PET findings.
Relying on CT alone may lead to a misdiagnosis of central
necrosis and can be adjudged as a response to chemotherapy
in an otherwise hypercellular mass. Several recent studies
have suggested that the addition of PET to conventional
imaging (chest, abdominal and pelvic CT, bone scan) may
increase sensitivity for the detection of distant metastasis and
lead to higher diagnostic accuracy for RMS staging [11–13].
Thus, inclusion of the upper abdomen on chest CT staging
evaluations of RMS patients, adjustments of abdominal CT
protocols toward better evaluation of the pancreas or
inclusion of PET/CT studies into staging evaluations of
patients with alveolar RMS should be considered to improve
the detection of these lesions.
This increased incidence of unusual metastases, including
pancreatic ones, has been noted by numerous authors in
pathology literature [1, 4, 5, 14–16]. It has been postulated
that RMS arising in the extremities, especially in the hand
and foot, can be particularly aggressive with multiple
metastases to unusual sites (e.g., breast, ovary, testes, kidney,
pancreas) that most commonly have alveolar histology and,
hence, worse prognosis [16]. The involvement of the
pancreas even in the absence of other abdominal metastases,
as seen in some of the cases presented here, raises the
possibility that there might be an underlying biological cause
for this pattern of metastatic spread. To the best of our
knowledge, all previously described cases of pancreatic
metastases in RMS were seen in tumors with alveolar
histology [7, 9, 10, 16]. IGF-II receptor expression has been
demonstrated on RMS cell lines [17–19]. It has also been
reported that the PAX/FKHR fusion protein characteristic of
alveolar RMS may induce transcription of IGF-I and other
growth factors, further suggesting autocrine mechanisms of
cellular proliferation [18, 19]. This observation may be
related to the known molecular alterations that are specific to
alveolar RMS, such as the PAX3/7—FKHR fusion gene.
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The pancreas is also heavily influenced by IGF and IGF-like
proteins. Such genetic associations also raise the possibility
that the pancreas may be a part of multiorgan tumor
involvement in susceptible tissues. This is further strength-
ened by the therapeutic effect of IGF-IR monoclonal
antibodies on soft tissue sarcoma, including RMS. Future
research should be directed towards better documenting and
eliciting this curious relationship.
Conclusion
Our retrospective review suggests that pancreatic metasta-
ses in patients with alveolar RMS may be more common
than previously reported. With this review, we intend to
sensitize pediatric radiologists to evaluate imaging studies
in these patients actively for pancreatic metastases. Further
prospective studies have to show if addition of PET-CT
evaluations will increase the sensitivity of standard imaging
procedures and ultimately improve outcome by earlier
detection of metastatic disease or disease recurrence.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
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